News & Updates

Intralesional botulinum toxin proven safe, effective in nail psoriasis

11 Jul 2023 by

A single injection of intralesional botulinum toxin (BTX) demonstrates long-term efficacy and is well tolerated in patients with nail psoriasis, according to a randomized intraindividual controlled study presented at the recent WCD 2023. BTX is also as effective as multiple intralesional steroid injections.

Intralesional botulinum toxin proven safe, effective in nail psoriasis

11 Jul 2023

Spesolimab curbs flares in generalized pustular psoriasis

10 Jul 2023 by

The anti-interleukin (IL)-36 receptor monoclonal antibody spesolimab not only helps treat generalized pustular psoriasis (GPP) flares but also prevent them, according to the results of the Effisayil 2 study presented at WCD 2023.

Spesolimab curbs flares in generalized pustular psoriasis

10 Jul 2023

Original New Drug Application Approvals by US FDA (16-30 June 2023)

01 Jul 2023

New drug applications approved by US FDA as of 16-30 June 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2023)

01 Jul 2023

New scorecard helps detect peanut allergy

27 Jun 2023 by

Paediatricians may have a new tool in a scorecard that could ably detect peanut allergy in infants with atopic dermatitis (AD).

New scorecard helps detect peanut allergy

27 Jun 2023

$Paroxetine safe, effective for refractory erythema of rosacea$

Paroxetine safe, effective for refractory erythema of rosacea

21 Jun 2023

Treatment with paroxetine is effective against moderate-to-severe erythema of rosacea and has no serious adverse effects, a study has shown.

Paroxetine safe, effective for refractory erythema of rosacea

21 Jun 2023

Which factors contribute to skin neoplasms in Lynch syndrome patients?

20 Jun 2023

Individuals with Lynch syndrome (LS) often develop skin neoplasms, reports a recent study, which has identified several clinical factors that contribute to LS- and non-LS-related skin neoplasms.

Which factors contribute to skin neoplasms in Lynch syndrome patients?

20 Jun 2023

Add-on mRNA cancer vaccine delivers promise for melanoma

20 Jun 2023 by

Adding mRNA-4157, an investigational personalized neoantigen cancer vaccine, to the immune checkpoint inhibitor (ICI) pembrolizumab significantly improved recurrence-free survival (RFS) in individuals with resected high-risk melanoma, findings from the phase IIb KEYNOTE 942 study suggest.

Add-on mRNA cancer vaccine delivers promise for melanoma

20 Jun 2023

Cutaneous eruptions from ibrutinib overlap with EGFR-induced adverse events

19 Jun 2023

Several cutaneous toxicities arising from ibrutinib therapy are similar to those caused by the use of selective epidermal growth factor receptor (EGFR) inhibitors, except for petechiae, according to a study.

Cutaneous eruptions from ibrutinib overlap with EGFR-induced adverse events

19 Jun 2023

Camrelizumab plus apatinib and temozolomide delivers in advanced acral melanoma

05 Jun 2023

The combination of camrelizumab plus apatinib and temozolomide appears to be beneficial in the first-line treatment of advanced acral melanoma, with the majority of the patients showing response and an acceptable safety profile, according to the results of a phase II study.

Camrelizumab plus apatinib and temozolomide delivers in advanced acral melanoma

05 Jun 2023

Atopic dermatitis poses heightened risk of venous thromboembolism

03 Jun 2023

Adults with atopic dermatitis appear to have an increased risk of venous thromboembolism (VTE), although the risk difference relative to adults without AD is quite small, as reported in a study.

Atopic dermatitis poses heightened risk of venous thromboembolism

03 Jun 2023

News & Updates

Filter by Specialty:

Specialty:

Intralesional botulinum toxin proven safe, effective in nail psoriasis

Intralesional botulinum toxin proven safe, effective in nail psoriasis

Spesolimab curbs flares in generalized pustular psoriasis

Spesolimab curbs flares in generalized pustular psoriasis

Original New Drug Application Approvals by US FDA (16-30 June 2023)

Original New Drug Application Approvals by US FDA (16-30 June 2023)

New scorecard helps detect peanut allergy

New scorecard helps detect peanut allergy

Paroxetine safe, effective for refractory erythema of rosacea

Paroxetine safe, effective for refractory erythema of rosacea

Which factors contribute to skin neoplasms in Lynch syndrome patients?

Which factors contribute to skin neoplasms in Lynch syndrome patients?

Add-on mRNA cancer vaccine delivers promise for melanoma

Add-on mRNA cancer vaccine delivers promise for melanoma

Cutaneous eruptions from ibrutinib overlap with EGFR-induced adverse events

Cutaneous eruptions from ibrutinib overlap with EGFR-induced adverse events

Camrelizumab plus apatinib and temozolomide delivers in advanced acral melanoma

Camrelizumab plus apatinib and temozolomide delivers in advanced acral melanoma

Atopic dermatitis poses heightened risk of venous thromboembolism

Atopic dermatitis poses heightened risk of venous thromboembolism